Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OVR044
MIFTS: 36

Ovarian Carcinosarcoma

Categories: Rare diseases, Reproductive diseases, Endocrine diseases, Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ovarian Carcinosarcoma

About this section

MalaCards integrated aliases for Ovarian Carcinosarcoma:

Name: Ovarian Carcinosarcoma 12 53 59 15
Ovarian Malignant Mixed Epithelial Mesenchymal Tumor 53 59
Malignant Mixed Müllerian Tumor of the Ovary 53 59
Ovarian Malignant Mixed Müllerian Tumor 53 59
Mmmt of the Ovary 53 59
Malignant Mixed Mullerian Tumor of the Ovary 53
Ovarian Malignant Mesodermal Mixed Tumor 12
Ovarian Malignant Mixed Mullerian Tumor 12
Carcinosarcoma of Ovary 73
Ovarian Mmmt 12

Characteristics:

Orphanet epidemiological data:

59
malignant mixed müllerian tumor of the ovary
Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:6170
NCIt 50 C9192
SNOMED-CT 68 702368000
Orphanet 59 ORPHA213512
UMLS via Orphanet 74 C0392998
ICD10 via Orphanet 34 C56
UMLS 73 C0392998
Sources

Summaries for Ovarian Carcinosarcoma

About this section
NIH Rare Diseases : 53 Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of ovarian carcinosarcoma is not yet understood. Treatment usually consists of surgery to remove the tumor and chemotherapy. The chance of recovery and long-term survival (prognosis) is poor, with a reported 5-year survival rate of about 28%.

MalaCards based summary : Ovarian Carcinosarcoma, also known as ovarian malignant mixed epithelial mesenchymal tumor, is related to cystic teratoma and teratoma. An important gene associated with Ovarian Carcinosarcoma is TUBB3 (Tubulin Beta 3 Class III), and among its related pathways/superpathways is Neuroscience. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and brain.

Sources

Related Diseases for Ovarian Carcinosarcoma

About this section

Diseases related to Ovarian Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 cystic teratoma 29.8 ENO2 SYP
2 teratoma 29.4 ENO2 SYP
3 chondroid chordoma 10.3 ENO2 TUBB3
4 malignant mixed mullerian tumor 10.3
5 lymphoepithelioma-like carcinoma 10.3 CD274 ENO2
6 ureter small cell carcinoma 10.2 ENO2 SYP
7 malignant sertoli cell tumor 10.2 ENO2 SYP
8 urinary bladder small cell neuroendocrine carcinoma 10.2 ENO2 SYP
9 auditory system cancer 10.2 ENO2 SYP
10 sinonasal undifferentiated carcinoma 10.2 ENO2 SYP
11 sensory organ benign neoplasm 10.2 ENO2 SYP
12 gallbladder small cell carcinoma 10.2 ENO2 SYP
13 pancreatic somatostatinoma 10.2 ENO2 SYP
14 cutaneous ganglioneuroma 10.2 ENO2 SYP
15 extrahepatic bile duct adenocarcinoma 10.2 ENO2 SYP
16 small cell carcinoma of the bladder 10.2 ENO2 SYP
17 papillary tumor of the pineal region 10.2 ENO2 SYP
18 orbital cancer 10.2 ENO2 SYP
19 middle ear adenoma 10.2 ENO2 SYP
20 pulmonary large cell neuroendocrine carcinoma 10.2 ENO2 SYP
21 atypical follicular adenoma 10.2 ENO2 SYP
22 central nervous system primitive neuroectodermal neoplasm 10.2 ENO2 SYP
23 cerebellum cancer 10.2 ENO2 SYP
24 subependymal glioma 10.2 ENO2 SYP
25 cerebral neuroblastoma 10.2 ENO2 SYP
26 cauda equina neoplasm 10.2 ENO2 SYP
27 extraosseous chondrosarcoma 10.2 ENO2 SYP
28 benign ependymoma 10.2 ENO2 SYP
29 malignant teratoma 10.2 ENO2 SYP
30 astroblastoma 10.2 ENO2 SYP
31 cerebral ventricle cancer 10.2 ENO2 SYP
32 cerebrum cancer 10.2 ENO2 SYP
33 endometrial small cell carcinoma 10.2 ENO2 SYP
34 melanotic neuroectodermal tumor 10.2 ENO2 SYP
35 nodular ganglioneuroblastoma 10.2 ENO2 SYP
36 supratentorial cancer 10.1 ENO2 SYP
37 mucinous ovarian cystadenoma 10.1 ENO2 SYP
38 respiratory system benign neoplasm 10.1 ENO2 SYP
39 angiomyoma 10.1 ENO2 SYP
40 gastric squamous cell carcinoma 10.1 ENO2 SYP
41 gastric small cell carcinoma 10.1 ENO2 SYP
42 desmoplastic small round cell tumor 10.1 ENO2 SYP
43 subependymoma 10.1 ENO2 SYP
44 carcinoid tumors, intestinal 10.1 ENO2 SYP
45 bone benign neoplasm 10.1 ENO2 SYP
46 meningeal melanomatosis 10.1 ENO2 SYP
47 cervical clear cell adenocarcinoma 10.1 ENO2 SYP
48 papillary ependymoma 10.1 ENO2 SYP
49 extraskeletal ewing sarcoma 10.1 ENO2 SYP
50 connective tissue benign neoplasm 10.1 ENO2 SYP

Graphical network of the top 20 diseases related to Ovarian Carcinosarcoma:



Diseases related to Ovarian Carcinosarcoma
Sources

Symptoms & Phenotypes for Ovarian Carcinosarcoma

About this section
Sources

Drugs & Therapeutics for Ovarian Carcinosarcoma

About this section

Drugs for Ovarian Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
4
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
5
Ifosfamide Approved Phase 3 3778-73-2 3690
6
Cyproheptadine Approved Phase 3 129-03-3 2913
7
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
8 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
9 Antimitotic Agents Phase 3,Phase 2,Phase 1
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
11 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
12 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
13
Isophosphamide mustard Phase 3 0
14 Alkylating Agents Phase 3,Phase 2
15 Antineoplastic Agents, Alkylating Phase 3,Phase 2
16
Histamine Phosphate Phase 3 51-74-1 65513
17 Serotonin Agents Phase 3
18 Serotonin Antagonists Phase 3
19 Gastrointestinal Agents Phase 3
20 Neurotransmitter Agents Phase 3
21 Histamine Antagonists Phase 3
22 Histamine H1 Antagonists Phase 3
23 Dermatologic Agents Phase 3
24 Anti-Allergic Agents Phase 3
25 Antipruritics Phase 3
26
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
27
Gemcitabine Approved Phase 2 95058-81-4 60750
28
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
29
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
30
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
31
Everolimus Approved Phase 2 159351-69-6 6442177
32
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
33
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
34
Doxil Approved June 1999 Phase 2,Phase 1 31703
35 Immunosuppressive Agents Phase 2
36 Anti-Infective Agents Phase 2
37 Antimetabolites Phase 2
38 Antiviral Agents Phase 2
39 Antimetabolites, Antineoplastic Phase 2
40 Mitogens Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 2,Phase 1
42 Endothelial Growth Factors Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 2,Phase 1
44 Antibiotics, Antitubercular Phase 2,Phase 1
45 Immunoglobulin G Phase 2,Phase 1
46 Antibodies Phase 2,Phase 1
47 Immunoglobulins Phase 2,Phase 1
48 Antibodies, Monoclonal Phase 2,Phase 1
49 Antifungal Agents Phase 2
50 Liver Extracts Phase 2

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
5 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
6 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
7 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
8 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
9 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
10 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
11 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
12 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
13 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
14 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
15 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
16 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
17 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
18 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
19 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
20 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
21 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Completed NCT00904514

Search NIH Clinical Center for Ovarian Carcinosarcoma

Sources

Genetic Tests for Ovarian Carcinosarcoma

About this section
Sources

Anatomical Context for Ovarian Carcinosarcoma

About this section

MalaCards organs/tissues related to Ovarian Carcinosarcoma:

41
Ovary, Liver, Brain, Endothelial, Small Intestine
Sources

Publications for Ovarian Carcinosarcoma

About this section

Articles related to Ovarian Carcinosarcoma:

(show all 46)
# Title Authors Year
1
Usefulness of ascites cytology for the evaluation of chemotherapy response in ovarian carcinosarcoma. ( 29488261 )
2018
2
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. ( 29426293 )
2018
3
Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma. ( 28791266 )
2017
4
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. ( 28679774 )
2017
5
Paraneoplastic cerebellar degeneration secondary to ovarian carcinosarcoma: a cerebellar conundrum. ( 28790096 )
2017
6
Clinical Significance of Programmed Death Liganda891 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. ( 28125702 )
2017
7
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. ( 27958685 )
2017
8
Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. ( 27107722 )
2016
9
Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma. ( 27807494 )
2016
10
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. ( 27791010 )
2016
11
Mature Teratoma Associated with Bilateral Ovarian Carcinosarcoma - Accidental Association or Etiopathogenetic Determinism? - Case Report. ( 27819640 )
2016
12
Presence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid. ( 25802693 )
2015
13
Ovarian carcinosarcoma: a case report, diagnosis, treatment and literature review. ( 27418786 )
2015
14
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. ( 25962155 )
2015
15
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTEAr), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. ( 26474755 )
2015
16
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. ( 25341582 )
2014
17
A rare case of ovarian carcinosarcoma with neuroendocrine differentiation. ( 24971408 )
2014
18
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. ( 24631447 )
2014
19
Ovarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor. ( 26052208 )
2014
20
Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma. ( 24587930 )
2014
21
Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report. ( 23722511 )
2013
22
Large polyp of the small intestine: an unexpected metastasis of ovarian carcinosarcoma. ( 23926191 )
2013
23
Prognostic determinants in patients with uterine and ovarian carcinosarcoma. ( 23947079 )
2013
24
Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. ( 23781249 )
2013
25
Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. ( 23450567 )
2013
26
Complete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of assessment of the response by FDG-PET. ( 24371621 )
2012
27
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. ( 22209775 )
2012
28
A rare case of ovarian carcinosarcoma successfully treated with the neoadjuvant chemotherapy of paclitaxel and ifosfamide. ( 21417665 )
2011
29
Solitary splenic metastasis from ovarian carcinosarcoma: a case report. ( 21310035 )
2011
30
Malignant melanoma arising in an ovarian carcinosarcoma: case report and review of the literature. ( 21293284 )
2011
31
Whole-body FDG PET/CT in diagnosis of internal mammary nodal metastasis of ovarian carcinosarcoma. ( 21552025 )
2011
32
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. ( 22075385 )
2011
33
Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. ( 19820383 )
2009
34
Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas. ( 18321361 )
2008
35
Current management of ovarian carcinosarcoma. ( 17362309 )
2007
36
Clinical features and outcomes of uterine and ovarian carcinosarcoma. ( 16271748 )
2006
37
Complete cytoreduction combined with early postoperative intraperitoneal chemotherapy for ovarian carcinosarcoma. Report of two cases. ( 16645301 )
2006
38
A case of primary ovarian carcinosarcoma and vulvar carcinoma with widespread lymphadenopathy. ( 16846899 )
2006
39
Clinicopathological features of ovarian carcinosarcomas: a single institution experience. ( 15589592 )
2005
40
Primary ovarian carcinosarcoma: a case report and review of the literature. ( 15493190 )
2004
41
Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. ( 12893202 )
2003
42
Unusual Trousseau's syndrome in ovarian carcinosarcoma: multiple systemic thromboembolic events. ( 12554280 )
2002
43
Borderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma. ( 12574850 )
2001
44
Ovarian carcinosarcoma [correction of carcinoma]. ( 11418412 )
2001
45
Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. ( 11119124 )
2000
46
MR images of ovarian carcinosarcoma. ( 10646984 )
1999
Sources

Variations for Ovarian Carcinosarcoma

About this section
Sources

Expression for Ovarian Carcinosarcoma

About this section
Search GEO for disease gene expression data for Ovarian Carcinosarcoma.
Sources

Pathways for Ovarian Carcinosarcoma

About this section

Pathways related to Ovarian Carcinosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.33 ENO2 SYP TUBB3
Sources

GO Terms for Ovarian Carcinosarcoma

About this section
Sources

Sources for Ovarian Carcinosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....